The U.S. Food and Drug Administration has approved Adstiladrin, which is being billed as the first gene therapy treating high-risk, non-muscle-invasive bladder cancer.
FDA approves first-ever bladder cancer gene therapy
The U.S. Food and Drug Administration has approved Adstiladrin, which is being billed as the first gene therapy treating high-risk, non-muscle-invasive bladder cancer.